Summary & Overview
HCPCS Level II S0178: Lomustine, Oral, 10 mg
HCPCS Level II code S0178 denotes lomustine, oral, 10 mg, a systemic chemotherapy agent used in oncology. Nationally, accurate reporting of this HCPCS Level II code supports appropriate pharmacy billing, coverage determinations, and patient access to oral anticancer therapy. This code matters for payers, providers, and pharmacy benefit managers because oral chemotherapy billing intersects medical and pharmacy benefit policies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for lomustine, common billing and service settings, and what to expect from payer coverage frameworks. The publication summarizes typical sites of service, common modifiers used in practice (where applicable), and notes on how this code fits into oncology service lines.
The report also outlines benchmarks and policy-relevant topics readers will learn: national coverage considerations for oral chemotherapy, typical claims processing pathways (medical benefit versus pharmacy benefit), and documentation points that influence medical necessity adjudication. Data not available in the input is clearly indicated where applicable.
Billing Code Overview
HCPCS Level II code S0178 represents lomustine, oral, 10 mg, an orally administered alkylating chemotherapy agent used in oncology care. The service type is oral anticancer medication (chemotherapy administration via oral prescription). The typical site of service for this medication is outpatient pharmacy dispensing and outpatient oncology clinic or physician office for treatment planning and follow-up, with administration taking place at home by the patient after dispensing.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of recurrent glioblastoma is prescribed oral lomustine (S0178, lomustine 10 mg) as part of a chemotherapeutic regimen for central nervous system malignancy. The patient is evaluated in the oncology clinic by a medical oncologist or neuro-oncologist, who documents tumor status, prior therapies, laboratory values (complete blood count, liver function tests), and performance status. The prescription for lomustine is written for an individualized dose based on body surface area and prior alkylator exposure; the medication is dispensed by the oncology infusion center’s pharmacy or an outpatient specialty pharmacy and administered orally at home. Nursing staff provide counseling on timing of administration, expected toxicities (myelosuppression, hepatic dysfunction), and required monitoring schedule. Follow-up visits include interval labs to assess blood counts and liver enzymes, toxicity assessment, and documentation of dose modifications or treatment delays. Billing uses HCPCS Level II code S0178 to reflect supply of lomustine 10 mg for outpatient pharmacy or clinic-administered oral antineoplastic therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resources for care coordination or complex medication management for lomustine exceed typical expectations (rare for oral drug supply billing). |